In an un­usu­al move, ICER re­scinds draft re­port on JAK drugs for rheuma­toid arthri­tis to re­vise its mod­el­ing ap­proach

Two years ago, the In­sti­tute for Clin­i­cal and Eco­nom­ic Re­view (ICER) ad­mon­ished Ab­b­Vie for over­pric­ing the best-sell­ing drug in the world — Hu­mi­ra — along with the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.